PTC Therapeutics (PTCT) shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 ...

Onctura has dosed the first subject in the open-label Phase II OCULE-01 trial of oral roginolisib in individuals with rare ...

Design Three arm, open label, pragmatic, multicentre, randomised, phase 3 superiority trial (BASIL-3). Setting 35 UK NHS vascular units. Participants Patients with chronic limb threatening ischaemia ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Report of the Meeting of the Eastern Branch of the Provincial Association at Bury St. Edmond's ...

The COMMANDS study (NCT03682536) - a phase 3 open-label, randomised trial to evaluate the efficacy and safety of Reblozyl versus epoetin alfa - demonstrated high statistical significance and ...

However, as the load power requirements go into the 10 KW and higher range, that single-phase AC line becomes inefficient at delivering power to the road. This is especially the case for loads such as ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...